Phase II Trial of Gemcitabine, Prednisone, and Zoledronic Acid in Pretreated Patients with Hormone Refractory Prostate Cancer

Urology

Volumn 69, Issue 2, 2007, Pages 347-351

  Di Lorenzo, Giuseppe ^a   Autorino, Riccardo ^b   Giuliano, Mario ^a   Morelli, Emilio ^c   Giordano, Antonio ^a   Napodano, Giorgio ^a   Russo, Aniello ^d   Benincasa, Giuseppe ^d   D'Armiento, Massimino ^b   Altieri, Vincenzo ^a   De Placido, Sabino ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c Urologia   (Italy)

^d Ospedale San Luca   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIDEPRESSANT AGENT; BICALUTAMIDE; CLODRONIC ACID; DOCETAXEL; ESTROGEN DERIVATIVE; FLUTAMIDE; GEMCITABINE; GONADORELIN DERIVATIVE; MITOXANTRONE; MORPHINE; NARCOTIC AGENT; NAVELBINE; PAMIDRONIC ACID; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; TRANQUILIZER; ZOLEDRONIC ACID;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DEATH; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; HUMAN; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PAIN ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; PAIN MEASUREMENT; PALLIATIVE CARE; PREDNISONE; PROBABILITY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33847228810     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.10.007     Document Type: Article

References (20)

1. Jemal A., Tiwari R.C., Murray T., et al. Cancer statistics. CA Cancer J Clin 54 (2004) 8-15
2. Scher H.I., Steineck G., and Kelly W.K. Hormone refractory (D3) prostate cancer: refining the concept. Urology 46 (1995) 142-148
3. Crawford E.D., Rosenblum M., Ziada A.M., et al. Overview: hormone refractory prostate cancer. Urology 54 (2000) 1-7
4. Di Lorenzo G., and De Placido S. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy. Int J Immunol Pharm 19 (2006) 10-25
5. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
6. Petrilak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
7. Rosenberg J.E., and Small E.J. Second-line chemotherapy for hormone-refractory prostate cancer: has the time come?. Clin Prostate Cancer 3 (2004) 122-124
8. Abbruzzese J. Phase I studies with the novel nucleoside analog, gemcitabine. Semin Oncol 23 (1996) 25-31
9. Burris H., Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreas cancer: a randomised study. J Clin Oncol 15 (1997) 2403-2413
10. Saad F., Gleason D.M., Murray R., et al. A randomized, placebo controlled trial of zoledronic acid in patients with hormone refractory metastatic prostate carcinoma. J Natl Cancer Inst 94 (2002) 1458-1468
11. Cleeland C.S., and Ryan K.M. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 23 (1994) 129-138
12. Tong D., Gillick L., and Hendrickson F.R. The palliation of symptomatic osseous metastases: final results of the study by the Radiation Therapy Oncology Group. Cancer 50 (1982) 893-899
13. Kaplan Z.L., and Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
14. Morant R., Bernhard J., Maibach R., et al. for the Swiss Group for Clinical Cancer Research (SAKK): Response and palliation in a phase II trial of gemcitabine in hormone refractory metastatic carcinoma. Ann Oncol 11 (2000) 183-188
15. Qin Z.H., Yang G.W., Zhou F.G., et al. Short-term efficacy of combined chemotherapy of gemcitabine and cisplatin on advanced hormone refractory prostate cancer. Ai Zheng 23 (2004) 1700-1703
16. Sternberg C.N. Satraplatin in the treatment of hormone refractory prostate cancer. BJU Int 96 (2005) 990-994
17. Urakami S., Yoshino T., Kikuno N., et al. Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: a pilot study. Urology 65 (2005) 543-548
18. Di Lorenzo G., Pizza C., Autorino R., et al. Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer. Eur Urol 46 (2004) 712-716
19. Oh W.K., Hagmann E., Manola J., et al. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. Clin Cancer Res 11 (2005) 28-29
20. Petrylak D.P. Future directions in the treatment of androgen-independent prostate cancer. Urology 65 suppl 6A (2005) 8-12